You generated the data. Now comes the hard part.

Modern instruments are extraordinary at producing data — flow cytometry, spatial transcriptomics, sequencing, proteomics. Turning that data into something you can publish is where most labs get stuck. The expertise sits in a different department, the software feels like the cockpit of a space shuttle, and the deadline doesn't care.

Cytogence exists to close that gap.

A scientist who hit the same wall you're hitting

Cytogence was founded by Kenneth P. Hough, Ph.D., an immunologist who spent years on the wrong side of that gap. As a PhD student at UAB, he watched flow cytometry analysis get bottlenecked behind a single expensive, license-locked workstation — and on some projects, fall back to software that looked like it shipped on Windows 95. In 2013 he wrote his own flow analysis app, Cytopedia, to fix it. The prototype worked; PhD deadlines won. (It's back — today it's Cytogence FCS.)

The pattern repeated as his research moved from RNA-seq into ChIP-seq, ATAC-seq, proteomics, lipidomics, and finally multi-omics: powerful platforms, painful tools — built for statisticians, not for the researcher staring at a deadline. Every time, the instinct was the same: build the thing that makes this reliable and repeatable.

That instinct became a company. Kenneth founded Cytogence, Inc. in 2020 to do bioinformatics the way he'd always wanted it done — rigorous, reproducible, and actually usable.

Kenneth P. Hough, Ph.D., Founder and Principal Scientist of Cytogence

Kenneth P. Hough, Ph.D.

Founder & Principal Scientist

Kenneth is an immunologist who studied biochemistry at Worcester Polytechnic Institute and earned his Ph.D. at the University of Alabama at Birmingham. His 20+ peer-reviewed publications — including first-author work and a study in Nature Immunology — span immunology, cancer biology, and cell metabolism. He has spent his career on both sides of the data — at the bench generating it, and writing the software to make sense of it — and founded Cytogence to be the analysis partner he wished he'd had.

Backed by a real engineering team

In 2025, Cytogence merged into KeyQ, Inc. as its Bioinformatics Division. The two shared a backbone — cloud infrastructure and serious software engineering — so consolidating meant Cytogence's scientific work is now built on production-grade engineering, not one-off scripts.

The result is a simple division of labor: analysis is led by a published scientist, and the software behind it is built by an engineering team. Tools like Cytogence FCS, Atlas, and the free PrimerGenie all came out of real research problems we hit ourselves.

Visit KeyQ, Inc.

What you actually get

Biology and computation

Someone who has been the person at the bench and the person writing the pipeline. We understand the experiment behind the data, not just the file format.

Reproducible by default

Production-grade pipelines with full provenance — every figure traceable to its data, parameters, and code version. Built to survive reviewer #2.

Publication-ready

We meet you wherever your data is and take it all the way to figures, tables, and methods your reviewers and co-authors will trust.

Let's move your research forward

Tell us about your project and we'll work with you to design the right analysis approach. Run a core facility? We partner with facilities that need an analysis pressure-release valve.

Get in Touch

Stay in the loop

Practical bioinformatics write-ups from the Cytogence team — a few times a month. No spam, unsubscribe anytime.